查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2028 年的肺動脈高壓市場預測——COVID-19 的影響以及按藥劑、類型、給藥途徑和分銷渠道進行的全球分析
市場調查報告書
商品編碼
1187270

到 2028 年的肺動脈高壓市場預測——COVID-19 的影響以及按藥劑、類型、給藥途徑和分銷渠道進行的全球分析

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs, Type, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 174 Pages | 商品交期: 1-5個工作天內

價格

肺動脈高壓市場預計將從 2021 年的 736989 萬美元增長到 2028 年的 1088908 萬美元，預計 2022 年至 2028 年的複合年增長率為 5.8%。 肺動脈高壓發病率上升和治療肺動脈高壓藥物的批准增加推動了市場增長。 然而，用於治療肺動脈高壓的藥物的副作用阻礙了市場增長。

肺動脈高壓 (PAH) 是一種罕見的進行性疾病，由肺動脈高壓（高血壓）引起。 由於多種原因，小肺動脈阻塞可能導致血管內壓升高。 PAH 的確切病因尚不清楚，雖然它是可以治療的，但它不是一種永久性疾病。 PAH 通常影響 30 至 60 歲的女性。

專利到期將使仿製藥進入肺動脈高壓市場，豐富產品線。 未來7-8年到2030年，專利到期的產品有望上市。 這將是未來幾年仿製藥公司的一個巨大機遇。 Gilead Sciences 的 Ambrisentan + Tadalafil用於治療PAH，但其專利將於2027年12月11日到期。 Care Ratings 發現許多製藥公司已經在開發其專利產品的仿製藥。 專利到期後，仿製藥就可以使用了。 雖然消費者受益於較低的價格，但專利保護的喪失使製藥公司面臨更激烈的競爭。 因此，預計專利到期將為仿製藥製造商在預測期內進入新市場提供機會。

此外，在過去 20 年中出現了 14 種經 FDA 批准的治療 PAH 的療法，這是一項重大成就，因為該病的人群較少。這是有可能的。 成功開發 PAH 療法的關鍵是在理解該疾病的遺傳和分子機制方面取得重大進展。 隨著這種意識的增強，治療策略也將繼續發展，並從目前專注於血管收縮的範例中多樣化。 臨床試驗正在探索新輸送裝置的臨床療效及其在其他肺動脈高壓和聯合療法中的應用。 這很可能成為未來臨床試驗的標準。

基於給藥途徑的見解

根據給藥途徑，肺動脈高壓市場分為口服、靜脈/皮下和吸入。 口腔部分將在 2021 年佔據最大的肺動脈高壓市場份額，預計在預測期內的複合年增長率最高。 用於治療症狀性中度至重度 PAH 的口服藥物包括西地那非和內皮素 (ET) 受體拮抗劑 (ERA)、波生坦和西他生坦，與波生坦相比增加了 ET 受體親和力。選擇性時代。 此外，用於治療 PAH 的新型口服藥物包括 machitentan、riociguat 和 treprostinil。 Ambrisentan 是一種內皮素受體拮抗劑，適用於治療 PAH（WHO 第 1 類），可以延緩臨床惡化。 安立生坦與他達拉非聯合使用可降低因疾病進展和 PAH 加重而住院的風險，並可改善運動成績。

在預測期內，北美肺動脈高壓市場所佔份額最大。 該地區的市場增長歸因於肺動脈高壓的高患病率、政府和製造商的舉措。 美國肺動脈高壓市場在區域市場中佔有很大份額。 儘管是一種罕見疾病，但 PAH 在美國的患病率要高得多。 據美國肺臟協會稱，肺動脈高壓是一種罕見的進行性疾病，美國每年約有 500 至 1,000 例新診斷病例。 據該協會稱，由於基因突變，15-20%的肺動脈高壓患者是遺傳性肺動脈高壓。

此外，製造商正在努力為醫療保健專業人員提供信息和資源，這推動了市場的增長。 由 United Therapeutics 支持的 PAH Initiative 提供資源和信息，以協助醫療保健專業人員治療 PAH 患者。 此外，美國肺動脈高壓科學登記處作為美國第一個 PAH 患者登記處成立，用於檢查患者群體的遺傳信息、生育史和環境暴露數據。 因此，每年診斷出的 PAH 病例數量不斷增加，以及製造商的努力，正在推動對肺動脈高壓藥物和其他治療方式的需求，導緻美國肺動脈高壓的上升，進一步推動市場增長。

加拿大在北美肺動脈高壓市場佔有第二大份額。 加拿大的肺動脈高壓患病率很高。 據 PHA Canada 估計，該國約有 10,000 人患有肺動脈高壓 (PH)，但已診斷出約 5,000 人。 加拿大批准了有限數量的藥物來減緩肺動脈高壓的進展或緩解症狀。 在過去 20 年中，加拿大僅批准了 10 種 PAH 治療方法。 但是，全國各地都有專門治療成人和兒童 PAH 的中心。 此外，發表在《歐洲呼吸雜誌》(2022) 上的一項研究報告稱，加拿大 PAH 人群的 1 年、3 年和 5 年生存率分別為 89.2%、75.6% 和 56.0%。 因此，據報導，加拿大的 PAH 患者長期死亡率很高。

世界衛生組織 (WHO)、美國食品和藥物管理局 (FDA)、美國罕見病組織 (NORD) 和其他組織在準備關於肺動脈高壓市場的報告時參考了主要和次要信息。

內容

第一章介紹

  • 調查範圍
  • Insight Partners 研究報告指南
  • 市場細分
    • 全球肺動脈高壓市場 - 按藥物分類
    • 全球肺動脈高壓市場 - 按類型
    • 全球肺動脈高壓市場 - 按給藥途徑
    • 全球肺動脈高壓市場 - 按分銷渠道
    • 全球肺動脈高壓市場 - 按地區

第 2 章肺動脈高壓市場——要點

第三章研究方法論

  • 範圍
  • 二次調查
  • 初步調查

第 4 章肺動脈高壓市場——市場格局

  • 害蟲分析
    • 北美 PEST 分析
    • 歐洲 PEST 分析
    • 亞太地區 PEST 分析
    • 中東和非洲 PEST 分析
    • 拉丁美洲 PEST 分析
  • 專家意見

第 5 章肺動脈高壓市場 - 主要市場動態

  • 市場驅動力
    • 肺動脈高壓患病率增加
    • 肺動脈高壓藥物的批准增加
  • 市場製約因素
    • 用於治療肺動脈高壓的藥物的副作用
  • 市場機會
    • 專利到期時間的增加使得仿製藥可以以可承受的價格獲得
    • 醫藥專利到期數據
  • 未來趨勢
    • 肺動脈高壓藥物開發的臨床試驗增加
  • 影響分析

第 6 章肺動脈高壓市場 - 全球分析

  • 肺動脈高壓全球市場收入、預測和分析
  • 全球肺動脈高壓市場：按地區劃分的預測和分析
  • 主要參與者的市場定位

第 7 章：全球肺動脈高壓市場 - 收入和到 2028 年的預測 - 按代理

  • 2021 年和 2028 年肺動脈高壓市場收入份額（按藥物）（%）
  • 內皮素受體拮抗劑 (ERA)
  • 前列環素和前列環素類似物
  • SGC 興奮劑
  • Pde-5 試紙

第 8 章全球肺動脈高壓市場分析和預測到 2028 年 - 按類型

  • 2021 年和 2028 年按類型劃分的全球肺動脈高壓市場 (%)
  • 品牌產品
  • 仿製藥

第 9 章全球肺動脈高壓市場 - 收入和到 2028 年的預測 - 按給藥途徑

  • 2021 年和 2028 年按給藥途徑劃分的肺動脈高壓市場收入份額 (%)
  • 口服劑
  • 靜脈內/皮下
  • 吸入給藥

第 10 章全球肺動脈高壓市場 - 到 2028 年的收入和預測 - 按分銷渠道

  • 2021 年和 2028 年肺動脈高壓市場收入份額（按分銷渠道）(%)
  • 醫院藥房/診所
  • 在線藥店
  • 零售藥房

第 11 章肺動脈高壓市場 - 收入和到 2028 年的預測 - 區域分析

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿聯酋
    • 沙特阿拉伯
    • 南非
    • 其他中東和非洲地區

第 12 章 COVID-19 大流行對肺動脈高壓市場的影響

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第 13 章肺動脈高壓市場 - 行業格局

  • 肺動脈高壓市場增長戰略 (%)
  • 有機部署
  • 無機開發

第14章公司簡介

  • Johnson & Johnson
  • Gilead Sciences Inc
  • United Therapeutics Corp
  • Bayer AG
  • Aerami Therapeutics Holdings Inc
  • Novartis AG
  • GSK Plc
  • Teva Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Pfizer Inc

第15章附錄

  • 關於 Insight Partners
  • 詞彙表
Product Code: TIPRE00005221

The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028. The market growth is attributed to the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs. However, the side effects of drugs used to treat pulmonary arterial hypertension hamper the market growth.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused due to high blood pressure (hypertension) in the arteries of the lungs. The increased pressure in the vessels may be caused by an obstruction in the small arteries in the lung for various reasons. The exact cause of PAH is unknown and although treatable; there is no permanent cure for the disease. PAH usually affects women between the age of 30-60 years..

Patent expiry permits generic drugs to penetrate the pulmonary arterial hypertension market and diversify product offerings. Over the next seven-eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. AMBRISENTAN + TADALAFIL drug by Gilead Sciences, Inc. is used to treat PAH, and its patent will be expired by December 11, 2027. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open an opportunity for generic drug manufacturers to enter a new market during the forecast period.

Moreover, over the past 20 years, the arrival of 14 FDA-approved therapies for treating PAH is seen as a major feat considering that this disease affects a small population. The key to success in developing PAH therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing awareness, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future.

Route of Administration-Based Insights

Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest pulmonary arterial hypertension market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability..

The pulmonary arterial hypertension market in North America held the largest share in the forecast period. The market growth in the region is attributed to the high prevalence of pulmonary arterial hypertension and initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share of the regional market. The prevalence of PAH in the US is much higher, although it is a rare disease. According to the American Lung Association, PAH is a rare and progressive disorder that accounts for about 500-1,000 new cases being diagnosed each year in the US. Additionally, as per the same source, ~15-20% of PAH patients have heritable PAH caused by genetic mutations.

Further, manufacturers undergo various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. The PAH Initiative supported by United Therapeutics provides resources and information to assist healthcare providers in treating patients affected by PAH. In addition, the United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a patient population. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

Canada holds the second-largest share of the pulmonary arterial hypertension market in North America. Canada has a high prevalence of pulmonary arterial hypertension. According to the PHA Canada, it is estimated that ~10,000 population in the country are affected by pulmonary hypertension (PH), but ~5,000 have been diagnosed with it. A limited number of treatments are approved in Canada to slow the progression of PH and alleviate symptoms. Over the last two decades, only 10 PH-specific medical treatments have been approved in Canada for treating PAH. However, the centers specializing in treating PAH in adults and children are located across the country. Additionally, a study (2022) published in European Respiratory Journal reported that the 1-, 3- and 5-year survival rates in the Canadian PAH cohort were 89.2%, 75.6%, and 56.0%, respectively. Thus, PAH patients in Canada are reported to have a high death rate in the long term.

The World Health Organization (WHO), US Food and Drug Administration (FDA), and National Organization for Rare Disorders (NORD) are among the primary and secondary sources referred to while preparing the report on the pulmonary arterial hypertension market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pulmonary arterial hypertension market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Pulmonary Arterial Hypertension Market - By Drugs
    • 1.3.2 Global Pulmonary Arterial Hypertension Market - By Type
    • 1.3.3 Global Pulmonary Arterial Hypertension Market - By Route of Administration
    • 1.3.4 Global Pulmonary Arterial Hypertension Market - By Distribution Channel
    • 1.3.5 Global Pulmonary Arterial Hypertension Market - By Geography

2. Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Pulmonary Arterial Hypertension Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific PEST Analysis
    • 4.2.4 Middle East and Africa PEST Analysis
    • 4.2.5 South and Central America PEST Analysis
  • 4.3 Experts Opinion

5. Pulmonary Arterial Hypertension Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
    • 5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
  • 5.2 Market Restraints
    • 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
    • 5.3.2 Drugs Patents Expiration Data
  • 5.4 Future Trend
    • 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
  • 5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - Global Analysis

  • 6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
  • 6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis
  • 6.3 Market Positioning of Key Players

7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

  • 7.1 Overview
  • 7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • 7.3 Endothelin Receptor Antagonists (ERAs)
    • 7.3.1 Overview
    • 7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Prostacyclin and Prostacyclin Analogs
    • 7.4.1 Overview
    • 7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 SGC Stimulators
    • 7.5.1 Overview
    • 7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Pde-5 Dipsticks
    • 7.6.1 Overview
    • 7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

  • 8.1 Overview
  • 8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • 8.3 Branded
    • 8.3.1 Overview
    • 8.3.2 Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Generics
    • 8.4.1 Overview
    • 8.4.2 Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

  • 9.1 Overview
  • 9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • 9.3 Oral
    • 9.3.1 Overview
    • 9.3.2 Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Intravenous/ Subcutaneous
    • 9.4.1 Overview
    • 9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Inhalational
    • 9.5.1 Overview
    • 9.5.2 Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

  • 10.1 Overview
  • 10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • 10.3 Hospital Pharmacies and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Online Pharmacies
    • 10.4.1 Overview
    • 10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Retail Pharmacies
    • 10.5.1 Overview
    • 10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis

  • 11.1 North America: Pulmonary Arterial Hypertension Market
    • 11.1.1 Overview
    • 11.1.2 North America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.1 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.1.1 Overview
        • 11.1.6.1.2 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.2.1 Overview
        • 11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.3.1 Overview
        • 11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.2 Europe: Pulmonary Arterial Hypertension Market
    • 11.2.1 Overview
    • 11.2.2 Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.2.7.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.1.1 Overview
        • 11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.2.1 Overview
        • 11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.3.1 Overview
        • 11.2.7.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.4.1 Overview
        • 11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.5.1 Overview
        • 11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.6.1 Overview
        • 11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.3 Asia Pacific: Pulmonary Arterial Hypertension Market
    • 11.3.1 Overview
    • 11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.3.7.1 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.1.1 Overview
        • 11.3.7.1.2 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.2.1 Overview
        • 11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.3 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.3.1 Overview
        • 11.3.7.3.2 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.4.1 Overview
        • 11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.5 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.5.1 Overview
        • 11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.6.1 Overview
        • 11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.4 South and Central America Pulmonary Arterial Hypertension Market
    • 11.4.1 Overview
    • 11.4.2 South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.1.1 Overview
        • 11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.2.1 Overview
        • 11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.3.1 Overview
        • 11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  • 11.5 Middle East & Africa Pulmonary Arterial Hypertension Market
    • 11.5.1 Overview
    • 11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    • 11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    • 11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    • 11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
    • 11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
      • 11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.1.1 Overview
        • 11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.2.1 Overview
        • 11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.3.1 Overview
        • 11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
      • 11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
        • 11.5.7.4.1 Overview
        • 11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
        • 11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
        • 11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
        • 11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

  • 12.1 North America: Impact Assessment of COVID-19 Pandemic
  • 12.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 12.4 South & Central America: Impact Assessment of COVID-19 Pandemic
  • 12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

13. Pulmonary Arterial Hypertension Market - Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
  • 13.3 Organic Developments
    • 13.3.1 Overview
  • 13.4 Inorganic Developments
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Johnson & Johnson
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Gilead Sciences Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 United Therapeutics Corp
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Bayer AG
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Aerami Therapeutics Holdings Inc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 GSK Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Teva Pharmaceutical Industries Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Lupin Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Pfizer Inc
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Drugs Patents Expiration Data
  • Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. North America Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. US Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. US Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Canada Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 35. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 39. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 50. China Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 51. China Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 55. Japan Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 58. India Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 59. India Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 67. Australia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
  • Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 95. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
  • Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market
  • Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market
  • Table 112. Glossary of Terms

List Of Figures

  • Figure 1. Pulmonary Arterial Hypertension Market Segmentation
  • Figure 2. Pulmonary Arterial Hypertension Market - By Geography
  • Figure 3. Pulmonary Arterial Hypertension Market Overview
  • Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market
  • Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
  • Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)
  • Figure 7. Global Pulmonary Arterial Hypertension Market - Leading Country Markets (US$ Million)
  • Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape
  • Figure 9. North America: PEST Analysis
  • Figure 10. Europe: PEST Analysis
  • Figure 11. Asia Pacific: PEST Analysis
  • Figure 12. Middle East and Africa: PEST Analysis
  • Figure 13. South and Central America: PEST Analysis
  • Figure 14. Experts Opinion
  • Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
  • Figure 16. Global Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 17. Global Pulmonary Arterial Hypertension Market - By Geography Forecast and Analysis - 2022 - 2028
  • Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market
  • Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
  • Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
  • Figure 25. Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
  • Figure 28. Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
  • Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 36. North America Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 38. US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 42. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 44. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 54. India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  • Figure 61. Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)
  • Figure 66. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 68. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 70. Impact of COVID-19 Pandemic in North America Country Markets
  • Figure 71. Impact of COVID-19 Pandemic in European Country Markets
  • Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
  • Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries
  • Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets
  • Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)